EGFR and lung adenocarcinoma: Studies have found that lung adenocarcinomas sensitive to erlotinib often harbor EGFR mutations and that EGFR mutations are predictors of sensitivity to EGFR TKIs, increasing the treatment benefits; these results have recently been validated 38-41.